Catherine Novack

Stock Analyst at Jones Trading

(0.08)
# 2656
Out of 5,347 analysts
24
Total ratings
30.77%
Success rate
-6.62%
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
FEMY Femasys
Maintains: Buy
10 6
0.88 581.82% 2 May 13, 2025
RGLS Regulus Therapeutics
Downgrades: Hold
8 7
7.94 -11.84% 2 Apr 30, 2025
RLYB Rallybio
Downgrades: Hold
n/a
n/a n/a 1 Apr 15, 2025
PVLA Palvella Therapeutic...
Initiates Coverage On: Buy
45
24.23 85.72% 1 Mar 25, 2025
PRQR ProQR Therapeutics
Initiates Coverage On: Buy
11
1.66 562.65% 1 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
130
11.46 1034.38% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
40
9.9 304.04% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Nov 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Oct 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
12 16
6.01 166.22% 2 Sep 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
14
2.24 525% 1 Sep 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
5 13
2.89 349.83% 2 Aug 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
10
4.11 143.31% 1 Apr 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
22
1.71 1186.55% 1 Feb 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 2 Oct 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
160
2.67 5892.51% 1 Jul 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
11
n/a n/a 1 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
n/a n/a 1 Dec 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
45
n/a n/a 1 Oct 4, 2021